Literature DB >> 31383954

Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy.

Cong Huang1,2, Gang Song3,4, Huihui Wang5, Zhiyong Lin5, He Wang5, Guangjie Ji1,2, Shouyi Zhang6, Yuanshan Guo7, Jie Li8, Zhengqing Bao1,2, Peng Hong1,2, Yicong Du1,2, Peng Li9, Qun He1,2, Shiming He1,2, Yanqing Gong1,2, Xiaoying Wang10, Liqun Zhou11,12.   

Abstract

BACKGROUND: Lymph node invasion (LNI) is a strong adverse prognostic factor in prostate cancer (PCa). The purpose of this study was to evaluate the role of Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) scores for estimating the risk of LN metastasis. The study also aimed to investigate the additional value of PI-RADSv2 scores when used in combination with clinical nomograms for the prediction of LNI in patients with PCa.
METHODS: We retrospectively identified 308 patients who underwent multiparametric magnetic resonance imaging (mpMRI) and RP with pelvic lymph node dissection (PLND). Clinicopathological parameters and PI-RADSv2 scores were assessed. Univariate and multivariate logistic analyses were performed. The area under the receiver operating characteristic curves (AUCs) and decision curve analysis (DCA) were generated for assessing the incremental value of PI-RADSv2 scores combined with the Briganti and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms.
RESULTS: Overall, 20 (6.5%) patients had LNI. At univariate analysis, all clinicopathological characteristics and PI-RADSv2 scores were significantly associated to LNI (p < 0.04). However, multivariate analysis revealed that only PI-RADSv2 scores and percentage of positive cores were independently significant (p ≤ 0.006). The PI-RADSv2 score was the most accurate predictor (AUC, 80.2%). The threshold of PI-RADSv2 score was 5, which provided high sensitivity (18/20, 90.0%) and negative predictive value (203/205, 99.0%). When PI-RADSv2 scores were combined with Briganti and MSKCC nomograms, the AUC value increased from 75.1 to 86.3% and from 79.2 to 87.9%, respectively (p ≤ 0.001). The DCA also demonstrated that the two nomograms plus PI-RADSv2 scores improved clinical risk prediction of LNI.
CONCLUSIONS: The patients with a PI-RADSv2 score <5 were associated with a very low risk of LNI in PCa. Preoperative PI-RADSv2 scores could help improve the accuracy of clinical nomograms for predicting pelvic LN metastasis at radical prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31383954     DOI: 10.1038/s41391-019-0164-z

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  1 in total

Review 1.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

  1 in total
  3 in total

1.  Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.

Authors:  Haoxin Zheng; Qi Miao; Yongkai Liu; Sohrab Afshari Mirak; Melina Hosseiny; Fabien Scalzo; Steven S Raman; Kyunghyun Sung
Journal:  Eur Radiol       Date:  2022-03-03       Impact factor: 7.034

2.  Predictive model using prostate MRI findings can predict candidates for nerve sparing radical prostatectomy among low-intermediate risk prostate cancer patients.

Authors:  Gang Song; Mingjian Ruan; He Wang; Zhiyong Lin; Xiaoying Wang; Xueying Li; Peng Li; Yandong Wang; Binyi Zhou; Xuege Hu; Hua Liu; Hao Wang; Yinglu Guo
Journal:  Transl Androl Urol       Date:  2020-04

3.  Predictive model containing PI-RADS v2 score for postoperative seminal vesicle invasion among prostate cancer patients.

Authors:  Hao Wang; Mingjian Ruan; He Wang; Xueying Li; Xuege Hu; Hua Liu; Binyi Zhou; Gang Song
Journal:  Transl Androl Urol       Date:  2021-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.